We have 3 of 15 papers
We haven’t gathered this author’s papers yet. Follow them and we’ll fetch their work.
Not the right person? Other researchers publish under this name.
Chemical 8b may serve as a promising candidate for further anticancer research after demonstrating encouraging dual kinase inhibitory action and exhibiting a favorable selectivity profile for normal MCF-10A cells.
Two novel classes of hybrid quinazolin-2,4-diones 2–17, privileged with urea and/or carbamate moieties, as EGFR-TK inhibitors represent promising lead candidates for developing novel EGFR inhibitors for cancer treatment.
Compound 6b is identified as a promising lead candidate for further development as a VEGFR-2-targeted anticancer agent and stable backbone behavior, regulated ligand fluctuations, preserved structural compactness, and sustained hydrogen bonding within the 6b-VEGFR-2 complex are identified.
We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.
